The longevity and efficiency of Invivofectamine® 3.0 as a means to deliver nucleic acid for developing treatments for Age-Related Macular Degeneration

Researchers

Grant status

Completed

Grant start date

06/11/2015

Grant funding

  • 2015: $7,270 from Thermo Fisher Scientific Inc

Updated:  04 August 2021 / Responsible Officer:  Director (Research Services Division) / Page Contact:  Researchers